Sagimet reports Q3 2026 results as AURORA Phase 3 acne trial advances
Sagimet dosed its first patient in the pivotal AURORA Phase 3 trial of denifanstat in October 2026 and reported a pro forma cash balance of about $356 million meant to fund operations into mid-2029.
Sagimet Biosciences reported financial results for the quarter ended September 30, 2026, along with pipeline updates dated November 12, 2026.
In October 2026, Sagimet announced that the first patient had been dosed in its AURORA registrational U.S. Phase 3 clinical trial, testing once-daily denifanstat in adults and adolescents aged 12 years and older with moderate to severe acne.1 The company said it plans to enroll approximately 800 patients in AURORA, including roughly 450 adolescents aged 12 to 17 years.1 The trial is designed with three co-primary endpoints at week 12, and about 530 patients who complete the double-blind period will be eligible to continue into a 40-week open-label extension that will assess denifanstat's long-term safety.1 Sagimet said topline data from AURORA are expected in the second half of 2027.1
The company also highlighted 52-week results from a Phase 3 open-label extension trial run in China by license partner Ascletis, presented at EADV 2026. The data showed ongoing improvement across all measured efficacy endpoints, including a 57% IGA treatment success rate, a 72% reduction in total lesions, and a 77% reduction in inflammatory lesions, with no permanent discontinuations tied to adverse events.1
On the FASN inhibitor TVB-3567, the single- and multiple-ascending dose and food effect portions of its Phase 1 trial completed dosing with the drug generally well tolerated, while a biomarker-focused part of the study in acne patients continues; Phase 2 doses have been selected, and Sagimet expects to start a Phase 2 trial in acne patients before the end of 2026.1
On financing, Sagimet completed an underwritten offering of Series A common stock and pre-funded warrants in October 2026, raising about $115.0 million in gross proceeds before expenses.1 Pro forma cash, cash equivalents and marketable securities as of September 30 totaled $355.8 million, including $80.0 million in net proceeds from that October offering.1 The company said this is expected to fund current operations through mid-2029, covering the anticipated AURORA readout and a potential NDA submission.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.